ClinicalTrials.gg
CompletedNCT02290340MEDI8897 1bUpdated Sep 19, 2018Results posted

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

A Phase 1 interventional study of Placebo and MEDI8897 10 mg in Respiratory Syncytial Virus, sponsored by MedImmune LLC. Completed at 13 sites in 3 countries. Open to participants aged Up to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-19.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
Up to 12 Months
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy preterm infants.

Read the detailed description

This Phase 1b/2a study will be a dose-escalation design to begin data collection on PK and safety in children. The population to be enrolled is healthy preterm infants born between 32 weeks 0 days and 34 weeks 6 days gestation who would not receive RSV prophylaxis based on the American Academy of Pediatrics (AAP) or other local guidelines. These subjects will not be receiving palivizumab, allowing for a placebo comparator group to begin collecting data on incidence rates of RSV medically attended lower respiratory illness (MA-LRI) and efficacy. Enrollment is planned at approximately 20 sites in the USA, Chile, and South Africa.

02

Conditions studied

  • Respiratory Syncytial Virus

Keywords

  • Respiratory Syncytial Virus, RSV
03

In context

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted after MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 12 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy infants born between 32 weeks 0 days and 34 weeks 6 days gestational age
  • Infants who are entering their first RSV season at the time of screening

Key Exclusion Criteria:

  • Gestational age \< 32 weeks 0 days and >34 weeks 6 days
  • Meets AAP or other local criteria to receive commercial palivizumab
  • Any fever (≥ 100.4°F [≥ 38.0°C], regardless of route) or lower respiratory illness within 7 days prior to randomization
  • Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization
  • Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection
  • Receipt of palivizumab or any RSV vaccine, including maternal RSV vaccination
05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
151 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive placebo intramuscularly.

    Drug: Placebo

  • Experimental
    MEDI8897 10 mg

    Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.

    Drug: MEDI8897 10 mg

  • Experimental
    MEDI8897 25 mg

    Participants will receive a single dose of MEDI8897 25 mg intramuscularly.

    Drug: MEDI8897 25 mg

  • Experimental
    MEDI8897 50 mg

    Participants will receive a single dose of MEDI8897 50 mg intramuscularly.

    Drug: MEDI8897 50 mg

Interventions

  • DrugPlacebo

    Participants will receive placebo intramuscularly.

  • Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.

  • Participants will receive a single dose of MEDI8897 25 mg intramuscularly.

  • Participants will receive a single dose of MEDI8897 50 mg intramuscularly.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity of a participant who received MEDI8897. TEAEs and TESAEs were the events that occurred between administration of study drug (Day 1) and Day 361 that were absent before treatment or that worsened relative to pre-treatment state.

    Time frame: From Study Drug Administration (Day 1) Through the Follow-up Period (Day 361)

  2. Number of Participants With Treatment-Emergent Adverse Events of Special Interest

    An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator (that is, within 24 hrs of knowledge of the event) to the sponsor. The AESIs for this study were hepatic function abnormality meeting the definition of Hy's law, hypersensitivity reactions including anaphylaxis, immune complex disease, and thrombocytopenia. Treatment-emergent AESIs were collected from the time of dosing until Day 361 post-dose.

    Time frame: From Study Drug Administration (Day 1) Through the Follow-up Period (Day 361)

  3. Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events

    Laboratory abnormalities determined by the investigator to be clinically significant that occurred after study drug dosing through 151 days post-dose that were absent before treatment or that worsened relative to pre-treatment state were reported as TEAEs. Laboratory evaluations (haematology and serum chemistry) of blood samples were performed.

    Time frame: From Study Drug Administration (Day 1) Through the Follow-up Period (Day 151)

Secondary outcomes

  1. Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897

    The Tmax defined as time at which maximum observed concentration of MEDI8897 (Cmax) was observed.

    Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose

  2. Maximum Observed Serum Concentration (Cmax) of MEDI8897

    The Cmax is the maximum observed serum concentration of MEDI8897.

    Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose

  3. Area Under the Concentration-Time Curve From Day 1 to Day 151 (AUC [1-151]) of MEDI8897

    Area under the concentration-time curve of the MEDI8897 in serum over the time interval from day 1 to day 151 (AUC1-151).

    Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), and 150 (± 7) Post-dose

  4. Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI8897

    The pharmacokinetic (PK) parameter AUC (0-infinity) was estimated based on the serum concentrations of MEDI8897.

    Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose

  5. Terminal Elimination Half Life (t1/2) of MEDI8897

    Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the serum.

    Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose

  6. Extravascular Clearance (CL/F) of MEDI8897

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose

  7. Extravascular Volume of Distribution (Vz/F) of MEDI8897

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.

    Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose

  8. Number of Participants Positive for Anti-Drug Antibodies to MEDI8897

    A participant was considered ADA-positive if the participant had a positive reading at any time point post baseline. Titers greater than or equal to 50 were considered positive.

    Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 31, 151, and 361 Post-dose

07

Results

Posted Sep 19, 2018

Participant flow

Participants were recruited between January 2015 and September 2015 at 10 sites (USA, South Africa, and Chile) and followed for 1 year after dosing.

Participant flow — Overall Study
MilestonePlaceboMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Started1883132
Completed1683130
Not completed2002
Withdrew: Lost to follow-up0001
Withdrew: Withdrawal by subject1000
Withdrew: Other1001

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity of a participant who received MEDI8897. TEAEs and TESAEs were the events that occurred between administration of study drug (Day 1) and Day 361 that were absent before treatment or that worsened relative to pre-treatment state.

Time frame:
From Study Drug Administration (Day 1) Through the Follow-up Period (Day 361)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
TEAEs1753130
TESAEs0012
PrimaryNumber of Participants With Treatment-Emergent Adverse Events of Special Interest

An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator (that is, within 24 hrs of knowledge of the event) to the sponsor. The AESIs for this study were hepatic function abnormality meeting the definition of Hy's law, hypersensitivity reactions including anaphylaxis, immune complex disease, and thrombocytopenia. Treatment-emergent AESIs were collected from the time of dosing until Day 361 post-dose.

Time frame:
From Study Drug Administration (Day 1) Through the Follow-up Period (Day 361)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events of Special Interest
ParticipantsPlaceboMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Number of Participants With Treatment-Emergent Adverse Events of Special Interest0000
PrimaryNumber of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events

Laboratory abnormalities determined by the investigator to be clinically significant that occurred after study drug dosing through 151 days post-dose that were absent before treatment or that worsened relative to pre-treatment state were reported as TEAEs. Laboratory evaluations (haematology and serum chemistry) of blood samples were performed.

Time frame:
From Study Drug Administration (Day 1) Through the Follow-up Period (Day 151)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events
ParticipantsPlaceboMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Anaemia6084
Microcytic anaemia0003
Neutropenia0001
SecondaryTime to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897

The Tmax defined as time at which maximum observed concentration of MEDI8897 (Cmax) was observed.

Time frame:
Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Reported as:
Mean · Day
Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897
DayMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI88977.04 ± 0.06837.04 ± 0.3946.93 ± 0.549
SecondaryMaximum Observed Serum Concentration (Cmax) of MEDI8897

The Cmax is the maximum observed serum concentration of MEDI8897.

Time frame:
Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Reported as:
Mean · microgram per milliliter (mcg/mL)
Maximum Observed Serum Concentration (Cmax) of MEDI8897
microgram per milliliter (mcg/mL)MEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Maximum Observed Serum Concentration (Cmax) of MEDI889723.2 ± 9.2830.9 ± 10.471.7 ± 15.9
SecondaryArea Under the Concentration-Time Curve From Day 1 to Day 151 (AUC [1-151]) of MEDI8897

Area under the concentration-time curve of the MEDI8897 in serum over the time interval from day 1 to day 151 (AUC1-151).

Time frame:
Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), and 150 (± 7) Post-dose
Reported as:
Mean · Day*mcg/mL
Area Under the Concentration-Time Curve From Day 1 to Day 151 (AUC [1-151]) of MEDI8897
Day*mcg/mLMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Area Under the Concentration-Time Curve From Day 1 to Day 151 (AUC [1-151]) of MEDI88971940 ± 8092260 ± 8815470 ± 1440
SecondaryArea Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI8897

The pharmacokinetic (PK) parameter AUC (0-infinity) was estimated based on the serum concentrations of MEDI8897.

Time frame:
Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Reported as:
Mean · Day*mcg/mL
Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI8897
Day*mcg/mLMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI88972450 ± NA4320 ± 10707510 ± 1870
SecondaryTerminal Elimination Half Life (t1/2) of MEDI8897

Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the serum.

Time frame:
Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Reported as:
Mean · Day
Terminal Elimination Half Life (t1/2) of MEDI8897
DayMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Terminal Elimination Half Life (t1/2) of MEDI889772.9 ± NA66.2 ± 7.8362.5 ± 9.35
SecondaryExtravascular Clearance (CL/F) of MEDI8897

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.

Time frame:
Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Reported as:
Mean · mL/day
Extravascular Clearance (CL/F) of MEDI8897
mL/dayMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Extravascular Clearance (CL/F) of MEDI88974.08 ± NA6.05 ± 1.317.01 ± 1.57
SecondaryExtravascular Volume of Distribution (Vz/F) of MEDI8897

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.

Time frame:
Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Reported as:
Mean · mL
Extravascular Volume of Distribution (Vz/F) of MEDI8897
mLMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Extravascular Volume of Distribution (Vz/F) of MEDI8897429 ± NA581 ± 159633 ± 168
SecondaryNumber of Participants Positive for Anti-Drug Antibodies to MEDI8897

A participant was considered ADA-positive if the participant had a positive reading at any time point post baseline. Titers greater than or equal to 50 were considered positive.

Time frame:
Pre-dose at Baseline (Days -7 to -1) and on Days 31, 151, and 361 Post-dose
Reported as:
Count of participants · Participants
Number of Participants Positive for Anti-Drug Antibodies to MEDI8897
ParticipantsPlaceboMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Baseline1000
Day 310200
Day 1510000
Day 36101710

Adverse events

Collected over From Study Drug Administration (Day 1) Through the Follow-up Period (Day 361). Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/18 (0%)0/18 (0%)17/18 (94.4%)
MEDI8897 10 mg0/8 (0%)0/8 (0%)5/8 (62.5%)
MEDI8897 25 mg0/31 (0%)1/31 (3.2%)31/31 (100%)
MEDI8897 50 mg0/32 (0%)2/32 (6.3%)28/32 (87.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Febrile convulsionNervous system disorders0/180/80/312/32
Lower respiratory tract infectionInfections and infestations0/180/81/311/32
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlaceboMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mg
Upper respiratory tract infectionInfections and infestations12/184/823/3122/32
PyrexiaGeneral disorders3/183/88/315/32
BronchiolitisInfections and infestations1/183/83/316/32
Otitis mediaInfections and infestations4/183/87/315/32
Nasal congestionRespiratory, thoracic and mediastinal disorders1/183/83/312/32
GastroenteritisInfections and infestations4/182/811/318/32
CoughRespiratory, thoracic and mediastinal disorders4/181/811/316/32
AnaemiaBlood and lymphatic system disorders6/180/88/314/32
Candida nappy rashInfections and infestations1/180/89/312/32
RhinorrhoeaRespiratory, thoracic and mediastinal disorders3/180/89/313/32

Baseline characteristics

The As-treated Population included all participants who received any study drug.

Age, Continuous
Age, Continuous(Months)PlaceboMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mgTotal
Mean7.0 ± 2.64.2 ± 2.16.7 ± 2.76.9 ± 2.56.6 ± 2.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mgTotal
Female114191953
Male74121336
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboMEDI8897 10 mgMEDI8897 25 mgMEDI8897 50 mgTotal
American Indian or Alaska Native00011
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American101192151
White460212
More than one race01012
Unknown or Not Reported4011722
08

Study locations

13 sites
  • Research Site
    Anaheim, California, United States
  • Research Site
    Ontario, California, United States
  • Research Site
    Syracuse, New York, United States
  • Research Site
    Cleveland, Ohio, United States
  • Research Site
    Charleston, South Carolina, United States
  • Research Site
    Saint George, Utah, United States
  • Research Site
    Marshfield, Wisconsin, United States
  • Research Site
    Santiago, Chile
  • Research Site
    Valdivia, Chile
  • Research Site
    Cape Town, South Africa
  • Research Site
    East London, South Africa
  • Research Site
    Johannesburg, South Africa
  • Research Site
    Pretoria, South Africa
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in Sep 2016, 20 months.

Results were first posted in Sep 2018, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2014
First posted
Nov 14, 2014
StartActual
Jan 13, 2015
Primary completionActual
Sep 28, 2016
CompletionActual
Sep 28, 2016
Results first posted
Sep 19, 2018
Last update
Sep 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02290340
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Nov 14, 2014
Start date
Jan 13, 2015
Primary completion
Sep 28, 2016
Completion
Sep 28, 2016
Results posted
Sep 19, 2018
Last update
Sep 19, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion